Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;26(5):1504-1516.
doi: 10.1007/s10461-021-03504-5. Epub 2022 Jan 8.

Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria

Holly L Peay  1 , Stuart Rennie  2 , R Jean Cadigan  2 , Angela Gwaltney  3 , Thidarat Jupimai  4 , Nittaya Phanuphak  5   6 , Eugène Kroon  5   6 , Donn J Colby  6   7   8 , Nuchanart Ormsby  2 , Sinéad C Isaacson  2 , Sandhya Vasan  7   8 , Carlo Sacdalan  5   6 , Peeriya Prueksakaew  5   6 , Khunthalee Benjapornpong  5   6 , Jintanat Ananworanich  9 , Gail E Henderson  2
Affiliations

Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria

Holly L Peay et al. AIDS Behav. 2022 May.

Abstract

HIV remission trials often require temporary stopping of antiretroviral therapy (ART)-an approach called analytic treatment interruption (ATI). Trial designs resulting in viremia raise risks for participants and sexual partners. We conducted a survey on attitudes about remission trials, comparing ART resumption criteria (lower-risk "time to rebound" and higher-risk "sustained viremia") among participants from an acute HIV cohort in Thailand. Analyses included Wilcoxon-Ranks and multivariate logistic analysis. Most of 408 respondents supported ATI trials, with slightly higher approval of, and willingness to participate in, trials using time to rebound versus sustained viremia criteria. Less than half of respondents anticipated disclosing trial participation to partners and over half indicated uncertainty or unwillingness about whether partners would be willing to use PrEP. Willingness to participate was higher among those who rated higher trial approval, lower anticipated burden, and those expecting to make the decision independently. Our findings support acceptability of ATI trials among most respondents. Participant attitudes and anticipated behaviors, especially related to transmission risk, have implications for future trial design and informed consent.

Keywords: Analytic treatment interruption; Attitudes; Remission; Transmission; Willingness to participate.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest/Competing interests: DC has received research grant support from Gilead Sciences. All other authors report no conflicts of interest or competing interests.

Figures

Figure 1.
Figure 1.
Approval of and Willingness to Participate in ATI Trials Using Time to Rebound and Sustained Viremia Designs (n=408)
See this image and copyright information in PMC

References

    1. Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Current opinion in HIV and AIDS. 2018. - PubMed
    1. Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. Curr Opin HIV AIDS. 2018;13(5):422–7. - PMC - PubMed
    1. Muccini C, Crowell TA, Kroon E, Sacdalan C, Ramautarsing R, Seekaew P, et al. Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research. AIDS Research and Therapy. 2019. - PMC - PubMed
    1. Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher K, Jupimai T, et al. Ethics of treatment interruption trials in HIV cure research: Addressing the conundrum of risk/benefit assessment. J Med Ethics. 2018;44(4):270–6. - PMC - PubMed
    1. Henderson GE, Waltz M, Meagher K, Cadigan RJ, Jupimai T, Isaacson S, et al. Going off antiretroviral treatment in a closely monitored HIV “cure” trial: longitudinal assessments of acutely diagnosed trial participants and decliners. J Int AIDS Soc. 2019;22(3). - PMC - PubMed

Substances